During 2019 European Hematology Association (EHA) Congress, Oncopeptides presented updated interim data from the ongoing phase 1/2 ANCHOR study, data from its phase 1/2 O-12-M1 study and updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. These presentations as well as publications in the media are presented below. The ANCHOR and O-12-M1 Posters, the oral presentation of HORIZON by Professor Paul G. Richardson and several external links and videos regarding publications in the media.
Interview with Professor Paul G. Richardson
Article in Multiple Myeloma Hub
EHA 2019 | Updated analysis of the HORIZON phase II trial: Melflufen + dexamethasone for RRMM. See the article as a document below.
Article in MedCity News (BioPharma) – By Alaric DeArment:
Oncopeptides looks forward to updates on myeloma drug at European hematology conference
In a phone interview, CEO Jakob Lindberg indicated that data so far showed a study was doing well in terms of progression-free survival.
See link below.
Article in M2 Pharma:
Oncopeptides to present new data from phase 1/2 ANCHOR trail at 24th EHA Congress
Oncopeptides AB (STO:ONCO) on Friday announced the presentation of new data at the 24th Congress of the European Haematology Association (EHA) in Amsterdam, including updated interim data from the ongoing phase 1/2 ANCHOR study and data from its phase 1/2 O-12-M1 study.
The company said that interim data from its ongoing, pivotal phase 2 HORIZON trial will also be presented on 16 June 2019 as an oral presentation by Professor Paul G. Richardson, Professor of Medicine at Harvard Medical School and clinical programme leader, director of Clinical Research at the Jerome Lipper Multiple Myeloma Centre Dana-Farber Cancer Institute in Boston, Massachusetts, US.
The full posters presented at EHA can be found on the company webpage at https://www.oncopeptides.com/ Investors & media / Presentations / 2019 EHA.
According to the company, the results from the O-12-M1 study demonstrate that melflufen can offer disease stabilisation and favourable time to the next treatment. It is strategically important from a health economic perspective and supports the potential that melflufen may play an important role in the treatment of patients with RRMM.
ANCHOR is a phase 1/2 trial where melflufen and dexamethasone is dosed in combination with either bortezomib or daratumumab. All patients must have 1-4 prior lines of therapy and be refractory (or intolerant) to an immunomodulary agent (IMiD) or a proteasome inhibitor (PI) or both. This trial is currently open for enrolment at multiple sites globally.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat haematological cancers.